Refine
Has Fulltext
- yes (12)
Is part of the Bibliography
- yes (12)
Document Type
- Journal article (12) (remove)
Language
- English (12)
Keywords
- multiple myeloma (4)
- amplicon sequencing (2)
- AKT-signaling (1)
- Alpha therapy (1)
- Autoimmune diseases (1)
- B cells (1)
- Bioluminescence imaging (1)
- Bone marrow cells (1)
- Bone marrow transplantantation (1)
- Bone marrow transplantation (1)
- CD319 (1)
- CS1 (1)
- CXCR4 (1)
- CXCR4/SDF-1 (1)
- Cancer treatment (1)
- Expression (1)
- FDG PET/CT (1)
- Factor receptor (1)
- Graft-versus-leukemia (1)
- HD (1)
- KRAS (1)
- Lymphomas (1)
- MEK/ERK-signaling (1)
- MTB (1)
- MTX (1)
- R-CHOP (1)
- Regulatory-cells (1)
- Rheumatoid arthritis (1)
- Spleen (1)
- Suppression (1)
- T cells (1)
- Tumor-necrosis-factor (1)
- actin (1)
- acute graft-versus-host disease (1)
- acute myeloid leukaemia (1)
- alloreactive T cells (1)
- antigen loss (1)
- apoptosis (1)
- autologous transplantation (1)
- bone disease (1)
- cancer (1)
- cancer care (1)
- cell binding (1)
- cell staining (1)
- cells (1)
- chemokine receptor (1)
- complement system (1)
- cytotoxicity (1)
- enzyme-linked immunoassays (1)
- extramedullary disease (1)
- immunohistochemistry techniques (1)
- in vivo imaging (1)
- involvement (1)
- lymphoma (1)
- malignancies (1)
- mantle cell lymphoma (1)
- microenvironment (1)
- monoclonal antibody (1)
- mouse models (1)
- obinutuzumab (1)
- outcomes research (1)
- outreach (1)
- patient access (1)
- plasma cells (1)
- positron emission tomography (1)
- precision oncology (1)
- prediction (1)
- rare SNP (1)
- real world data (1)
- receptor tyrosine kinases (1)
- survival (1)
- transplantation (1)
- venetoclax (1)
Institute
- Pathologisches Institut (12) (remove)
Sonstige beteiligte Institutionen
Purpose
Patients suffering from aggressive systemic peripheral lymphoma with primary central nervous system involvement (PCL) are a rare and sparsely investigated population. Recommended treatment regimens include a combination of intrathecal and systemic chemotherapy as well as whole brain radiotherapy while offering relatively poor survival.
Methods
We conducted a single-center retrospective study that analyzed safety and outcome of 4 + 4 cycles Rituximab (R)-CHOP and R-high-dose Methotrexate (HD-MTX) for newly diagnosed, transplant-eligible patients ("Ping-Pong"), followed by Cytarabine (AraC)/Thiotepa (TT), BCNU/TT, and autologous hematologic stem cell transplantation (aHSCT). We retrospectively analyzed a set of 16 patients with high-intermediate or high-risk IPI status.
Results
Overall response rate to Ping-Pong was 100% measured by CT/MRI, including 93.75% complete remissions after BCNU/TT followed by PBSCT. One patient failed to qualify for high-dose chemotherapy due to progression when receiving Cytarabine/TT. All patients experienced grade III adverse events, 3 of them a grade IV adverse event. Estimated progression-free survival is 93.75% after a 4.8-year follow-up currently.
Conclusion
Our study suggests high effectivity of R-CHOP with mid-cycle MTX with aHSCT consolidation towards acceptable OS results in this challenging patient population.